Drug trial halted in bid to stop blood Cancer's return
NCT ID NCT04623216
Summary
This study tested a drug called sabatolimab, alone or with another drug, for people with acute myeloid leukemia (AML). The goal was to see if it could prevent the cancer from coming back in patients who had a small amount of leftover disease after a stem cell transplant. The trial was stopped early by the company, not for safety reasons, before it could finish enrolling all planned participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Hamburg, 20246, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Bergamo, BG, 24127, Italy
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
Conditions
Explore the condition pages connected to this study.